Skip to main content
OpenTrials
Completed

NCT Number: NCT03272607

Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention

Reducing medications and associated side effects in older adults: an electronic hospital-based intervention

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Foothills Medical Centre, Calgary, Calgary, Alberta, Canada

Loading trial locations.

About this study

Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada and up to 20% of return visits to the hospital within 30 days of discharge. Many ADEs are preventable or ameliorable through interventions to reduce inappropriate prescribing.

MedSafer, the intervention software, applies an electronic set of criteria, previously designed and piloted on one thousand (1000) hospitalized patients by a group of Quebec and Ontario internists, geriatricians, palliative care doctors and pharmacists, to identify potentially inappropriate medications (PIMs) in the hospitalized elderly and generate instructions for the patient and physician for safe discontinuation. The current study seeks to partially automate the deprescribing process and to demonstrate the efficacy of this type of intervention on adverse drug events at 30-days post hospital discharge.

At the time of hospitalization, the patient's medications, co-morbidities, and a measure of frailty will be entered into the MedSafer software which will output an individualized and prioritized deprescription plan for the most responsible physician's consideration. Any subsequent medication changes will be transmitted to relevant community physicians. The study will evaluate the impact of stopping PIMs on the occurrence of ADEs within 30 days of discharge, as compared to usual care.

This study will take place on the clinical teaching units (CTUs) at 11 hospitals from seven university hospital centres across Canada. Based on historical data, the investigators estimate a combined 5200 eligible patients per year with nearly 50% taking ten or more medications. Many will have multiple medical co-morbidities such as diabetes, heart disease, and renal insufficiency. A large portion will meet criteria for geriatric syndromes such as frailty and will be at high risk for the development of delirium, falls and functional decline. This population is ideal for a generalizable deprescribing study.

All patients aged 65 or older who meet inclusion/exclusion criteria will be enrolled. A trained research assistant will identify eligible patients and medications will be screened using MedSafer. A deprescribing plan will be generated for the CTU team containing the rationale for suggested medication changes and strategies for safe and successful deprescription. The CTU team will then decide, in conjunction with the patient/proxy and relevant consultants, whether to apply the suggested modifications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients aged 65 years and older
  • patients who take five or more medications in the community
  • patients who are cognitively impaired or otherwise unable to provide consent will still be included as this subpopulation of patients may be at greatest risk of ADEs because of their communication problems.

Exclusion criteria

  • patients who take four or fewer medications in the community
  • patients expected to die within 30 days or be transferred to a palliative care unit/another hospital
  • patients without provincial health insurance or who normally live outside that province
  • patients previously enrolled
  • inability for patient or proxy to speak English or French
  • no means of contacting patient or proxy post-discharge

Patients discharged from non-study units will be excluded unless that unit is a transitional care, rehabilitation, or post-acute care unit which bridges the gap between acute medical hospitalization and community services.

Treatment and study plan

Deprescribing opportunities

Other

An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.

Primary outcomes

  1. Adverse Drug Events within 30 days post-discharge (ascertained via telephone interviewer and adjudicated via clinician reviewers)

    Time frame: Interview performed 30-35 days post-discharge.

    Post-discharge telephone interview performed by trained personnel using a modification of the Australian two-step adverse reaction and drug event report.

    Two trained and blinded clinician reviewers will independently use the Leape and Bates approach to assess whether an ADE was present (yes/no) and if so what was the nature of the injury resulting from it using a four-point Likert scale (definitely preventable, probably preventable, probably not preventable, and definitely not preventable), and assess the probability that an event was attributable to a specific drug that was newly started, changed or continued during hospitalization. In cases of disagreement, a third trained and blinded clinician will review and determine the final assessment.

Secondary outcomes

  1. Number of potentially inappropriate medications

    Time frame: At hospital discharge and at 30-days post hospital discharge

    The absolute number of potentially inappropriate medications at discharge among patients who were identified as having a potentially inappropriate medication at admission and for who a deprescribing opportunity was generated and presented to the treating team

  2. Mortality within 30-days post discharge

    Time frame: 30-days post hospital discharge

    Death following hospital discharge

  3. Proportion of participants with one or more potentially inappropriate medications deprescribed

    Time frame: At hospital discharge

    Proportion of participants with one or more potentially inappropriate medications deprescribed at discharge between intervention and control

  4. Quality of sleep

    Time frame: 30 days post hospital discharge

    Quality of sleep measured by the PROMIS Sleep Disturbance 4a measured pre- and post-hospitalization compared between intervention and control

  5. Adverse events

    Time frame: 30 days post hospital discharge

    The proportion of patients who had one or more adverse events (falls, hospitalization, death, unplanned encounter with the healthcare system

  6. Falls post hospital discharge

    Time frame: 30 days post hospital

    The proportion of patients with one or more self-reported falls post hospital discharge

  7. Quality of life of participants

    Time frame: At 30-days post hospital discharge

    Quality of life as measured by EQ5D-5L and reported based on reported Canadian time trade-off values (from 0-1 with higher equal to better quality of life)

Other outcomes

  1. Death post hospital discharge

    Time frame: 30-days post hospital discharge

    Proportion of patients who died post-hospital discharge compared between the intervention and control groups

  2. Unplanned visits with the healthcare system

    Time frame: 30-days post hospital discharge

    Proportion of patients with any self-reported unplanned visit with the healthcare system compared between intervention and control (emergency room visits and hospitalizations)

  3. Total number of medications at 30-days

    Time frame: At 30-days post discharge

    Total number of mediations at 30 days (reported as median and interquartile range) compared between intervention and control

  4. Sensitivity analysis for adverse drug events

    Time frame: At 30-days post hospital discharge

    Proportion of participants with 1 or more adverse drug events as defined by 4 or more on the 6-point Leape and Bates Likert scale

  5. Proportion of potentially inappropriate medications that remained stopped

    Time frame: 30-days post hospital discharge

    Proportion of potentially inappropriate medications that remained stopped between intervention and control

Sponsors and collaborators

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Other

Collaborators

  • Canadian Institutes of Health Research (CIHR)
  • Foothills Medical Centre
  • Kingston Health Sciences Centre
  • The Ottawa Hospital
  • University Health Network, Toronto
  • University of Alberta
  • University of British Columbia

Registry information

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Sep 5, 2017
Registry last updated
May 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.